Exclusive: UnitedHealth eyes $1 billion deal to exit Latin America as insurer refocuses on US, sources say

UnitedHealth Group is seeking to sell its Banmedica subsidiary, which operates in Colombia and Chile, for approximately $1 billion amid increasing pressure following an earnings miss, a reported criminal probe, and significant losses from previous exits in Brazil and Peru. The company has received four non-binding bids from firms including Acon Investments, Patria Investments, Christus Health, and Auna, with a deadline for binding proposals expected in July. This move reflects UnitedHealth's strategic refocus on the U.S. market after incurring an $8.3 billion loss last year related to its South American operations.

Analysis

UnitedHealth Group (UNH) is actively seeking to divest its Latin American subsidiary, Banmedica, for approximately $1 billion, reflecting an urgent push to refocus on its U.S. operations amidst considerable corporate turmoil. The insurer has received four non-binding bids for Banmedica, which operates in Colombia and Chile with an annual EBITDA exceeding $200 million, and anticipates binding proposals by July. This sale is part of a broader strategic exit from Latin America, initiated in 2022, and follows divestitures in Brazil (2023) and Peru (March 2024). The urgency is underscored by a recent earnings miss, a Wall Street Journal report of a criminal investigation into alleged Medicare fraud (which UNH states it has not been notified of by the DOJ), and significant leadership instability, including a CEO ouster following the murder of his predecessor. These factors have contributed to a severe 25.5% decline in UNH's share price in May and a 40% drop year-to-date. UnitedHealth previously recorded an $8.3 billion loss in 2023 linked to its South American exits, with $7.1 billion from Brazil and $1.2 billion from Banmedica, largely due to foreign currency translation effects. The current $1 billion target for Banmedica, acquired in 2018 for approximately 12 times its EBITDA, signifies a notable reduction in value, highlighting the challenging circumstances. New CEO Steve Hemsley has publicly committed to rebuilding shareholder trust.

Key Decisions for Investors

• Consider the prospective $1 billion Banmedica sale as a necessary step for UnitedHealth to streamline operations and reduce exposure to Latin American market volatility, although the financial impact is minor compared to previous write-downs and the company's overall market capitalization.
• Closely monitor developments concerning the reported criminal investigation, the new CEO's ability to stabilize the company and execute the U.S. refocus strategy, as these factors represent significant ongoing risks and uncertainties for UnitedHealth's valuation.
• Given the substantial 40% year-to-date stock price decline, assess whether the current market valuation adequately incorporates the operational difficulties and legal overhangs, or if the strategic shift towards the core U.S. market could present a recovery inflection point pending tangible improvements.